Literature DB >> 16679101

Cardiovascular disease risk stratification with stress single-photon emission computed tomography technetium-99m tetrofosmin imaging in patients with the metabolic syndrome and diabetes mellitus.

Leslee J Shaw1, Daniel S Berman, Robert C Hendel, Naomi Alazraki, Elizabeth Krawczynska, Salvador Borges-Neto, Jamshid Maddahi, Manuel Cerqueira.   

Abstract

The metabolic syndrome represents a constellation of risk factors caused by insulin resistance, dyslipidemia, hypertension, and obesity, resulting in elevated coronary disease risk. From a multicenter prospective registry of 7,849 patients, the relation among the metabolic syndrome, diabetes, and risk stratification with stress technetium-99m tetrofosmin single photon-emission computed tomography (SPECT) was evaluated. The percentage of stress myocardial defects was calculated as < or = 5%, 5.1% to 10%, 10.1% to 15%, and > 15%. A Cox proportional-hazards model was used to estimate cardiovascular death or myocardial infarction (n = 752). Of 7,849 patients, 42% had the metabolic syndrome. Patients with the metabolic syndrome had an 84% 2-year event-free survival rate, lower than patients with normal metabolic status (p <0.0001). In patients with the metabolic syndrome, the percentage of moderate to severely abnormal SPECT findings ranged from 11% to 44% for those with 3 to 5 risk factors for the metabolic syndrome. There was an additive relation between the number of risk factors for the metabolic syndrome and the extent and severity of abnormalities in SPECT findings (p <0.0001). Patients with 5 risk factors for the metabolic syndrome were at the greatest risk, with hazard ratios from 7.8- to 14.1-fold for mild to severely abnormal SPECT findings. For diabetic patients requiring combined oral and insulin therapy, relative risk ratios increased from 15 to 21.4 for patients with > 5% to > 15% stress myocardial perfusion defects. In conclusion, cardiovascular prognosis is affected by the degree of metabolic dysfunction, and stress-induced reductions in myocardial perfusion provide an accurate means for near-term risk stratification.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679101     DOI: 10.1016/j.amjcard.2005.12.041

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

Review 1.  Prognosis in the era of comparative effectiveness research: where is nuclear cardiology now and where should it be?

Authors:  Leslee J Shaw; Fadi G Hage; Daniel S Berman; Rory Hachamovitch; Ami Iskandrian
Journal:  J Nucl Cardiol       Date:  2012-10       Impact factor: 5.952

2.  Transient ischemic dilation in SPECT myocardial perfusion imaging for prediction of severe coronary artery disease in diabetic patients.

Authors:  Mario Petretta; Wanda Acampa; Stefania Daniele; Maria Piera Petretta; Carmela Nappi; Roberta Assante; Emilia Zampella; Pierluigi Costanzo; Pasquale Perrone-Filardi; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2012-10-23       Impact factor: 5.952

3.  The prognosis for prognosis remains excellent.

Authors:  Christopher L Hansen
Journal:  J Nucl Cardiol       Date:  2013-08       Impact factor: 5.952

4.  Risk stratification based on J-ACCESS risk models with myocardial perfusion imaging: Risk versus outcomes of patients with chronic kidney disease.

Authors:  Kenichi Nakajima; Satoko Nakamura; Hiroki Hase; Yasuchika Takeishi; Shigeyuki Nishimura; Yuhei Kawano; Tsunehiko Nishimura
Journal:  J Nucl Cardiol       Date:  2018-06-12       Impact factor: 5.952

Review 5.  Diagnostic imaging in the management of patients with metabolic syndrome.

Authors:  Seo Rin Kim; Lilach O Lerman
Journal:  Transl Res       Date:  2017-11-22       Impact factor: 7.012

6.  Myocardial perfusion imaging and risk classification for coronary heart disease in diabetic patients. The IDIS study: a prospective, multicentre trial.

Authors:  Wanda Acampa; Mario Petretta; Laura Evangelista; Stefania Daniele; Evgjeni Xhoxhi; Maria Luisa De Rimini; Corrado Cittanti; Filippo Marranzano; Marco Spadafora; Sergio Baldari; Luigi Mansi; Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-23       Impact factor: 9.236

7.  Prognostic estimation of coronary artery disease risk with resting perfusion abnormalities and stress ischemia on myocardial perfusion SPECT.

Authors:  Leslee J Shaw; Robert C Hendel; Gary V Heller; Salvador Borges-Neto; Manuel Cerqueira; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2008-09-12       Impact factor: 5.952

8.  The prognostic value of cardiac SPECT performed at the primary care physician's office.

Authors:  Rami Doukky; Nathan Frogge; Gautam Balakrishnan; Kathleen Hayes; Fareed Moses Collado; Maria O Rangel; Richard G Trohman; Robert C Hendel
Journal:  J Nucl Cardiol       Date:  2013-03-09       Impact factor: 5.952

9.  Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT: J-ACCESS study.

Authors:  Tsunehiko Nishimura; Kenichi Nakajima; Hideo Kusuoka; Akira Yamashina; Shigeyuki Nishimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

10.  Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease.

Authors:  Victor L Serebruany; Alex Malinin; Stephen Ong; Dan Atar
Journal:  J Thromb Thrombolysis       Date:  2007-05-26       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.